Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) Other Operating Expenses: 2013-2025

Historic Other Operating Expenses for MediWound (MDWD) over the last 8 years, with Jun 2025 value amounting to $367,000.

  • MediWound's Other Operating Expenses fell 42.11% to $367,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $3.6 million, marking a year-over-year decrease of 15.57%. This contributed to the annual value of -$18,000 for FY2024, which is 108.53% down from last year.
  • MediWound's Other Operating Expenses amounted to $367,000 in Q2 2025, which was down 75.34% from $1.5 million recorded in Q4 2024.
  • In the past 5 years, MediWound's Other Operating Expenses registered a high of $1.5 million during Q4 2024, and its lowest value of $367,000 during Q2 2025.
  • For the 3-year period, MediWound's Other Operating Expenses averaged around $1.0 million, with its median value being $1.1 million (2024).
  • In the last 5 years, MediWound's Other Operating Expenses spiked by 45.67% in 2022 and then slumped by 53.99% in 2024.
  • Over the past 5 years, MediWound's Other Operating Expenses (Quarterly) stood at $872,000 in 2021, then spiked by 45.67% to $1.1 million in 2022, then grew by 14.53% to $1.2 million in 2023, then grew by 21.77% to $1.5 million in 2024, then crashed by 42.11% to $367,000 in 2025.
  • Its Other Operating Expenses was $367,000 in Q2 2025, compared to $1.5 million in Q4 2024 and $1.1 million in Q3 2024.